Cargando…
Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma
Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for patient stratification or evaluation of therapy resistance. Given the dynamic and heterogeneous nature of clear cell RCC (ccRCC), tumor biopsies p...
Autores principales: | Bade, Rory M., Schehr, Jennifer L., Emamekhoo, Hamid, Gibbs, Benjamin K., Rodems, Tamara S., Mannino, Matthew C., Desotelle, Joshua A., Heninger, Erika, Stahlfeld, Charlotte N., Sperger, Jamie M., Singh, Anupama, Wolfe, Serena K., Niles, David J., Arafat, Waddah, Steinharter, John A., Jason Abel, E., Beebe, David J., Wei, Xiao X., McKay, Rana R., Choueri, Toni K., Lang, Joshua M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410529/ https://www.ncbi.nlm.nih.gov/pubmed/33604999 http://dx.doi.org/10.1002/1878-0261.12931 |
Ejemplares similares
-
SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples
por: Rodems, Tamara S., et al.
Publicado: (2022) -
Integration of Magnetic Bead-Based Cell Selection
into Complex Isolations
por: Pezzi, Hannah M., et al.
Publicado: (2018) -
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer
por: Schehr, Jennifer L., et al.
Publicado: (2022) -
Reversible epigenetic alterations regulate class I HLA loss in prostate cancer
por: Rodems, Tamara S., et al.
Publicado: (2022) -
High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1
por: Schehr, Jennifer L., et al.
Publicado: (2016)